Navigation Links
Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
Date:11/5/2011

oss Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.  Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1 clinical trial in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and th
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... BETHESDA, Md. , Nov. 24, 2014 /PRNewswire/ ... property development company committed to the fostering and ... regarding  Spherix v. VTech Telecommunications Ltd.,  Case No. ... , Case No. 3:13-cv-03496-M, both in the United ... Texas . ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Apiscent ... supplier of fine chemical ingredients to the global ... launch of its new website, Apiscent.com. , The ... Apiscent Labs, clean design, easy navigation, rotating images ... Apiscent Labs stand out. , The ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was ... himself with great people and take risks to achieve ... marveled at his extraordinarily courageous attitude when taking on ... even with his death impending—that’s how he continued looking ... ultimately take his life. , Carrying on Sharp’s relentless ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 CannLabs, ... cloud based analytics and scientific testing methodologies relating to ... for a $750,000 line of credit from an existing ... pleased to have secured this commitment from one of ... Officer of CannLabs. “This capital will help accelerate our ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2
... - Third Wave Technologies reported a smaller net ... 2006, but the company experienced impressive growth in clinical molecular ... Wave, which develops molecular diagnostic products for use in clinical ... net loss of $22.3 million, or 54 cents per share, ...
... Ken Rheingans' most immediate focus is next weekend's BarCamp ... BarCamp USA , the state's first national technology unconference. ... which will be held August 23-26 on the Jefferson County ... , said organizers would like to draw 5,000 technologists to ...
... this month's meeting of the Wisconsin Innovation Network ... Taxpayers Alliance was asked what single thing was standing ... the state average. , ,Berry, whose organization has been charting ... didn't give a predictable answer about high taxes. Instead, the ...
Cached Biology Technology:Third Wave reports net loss of $18.9M for 2006 2Wisconsin to host technology BarCamp USA 2Wisconsin to host technology BarCamp USA 3Education is fundamental to Milwaukee's growth 2Education is fundamental to Milwaukee's growth 3Education is fundamental to Milwaukee's growth 4
(Date:11/5/2014)... Rio de Janeiro, Brazil -Individuals show great diversity in ... importantly, males and females greatly differ in their perceptual ... kinds of smell tests. , Sex differences ... social behaviors and may be connected to one,s perception ... and emotions. Thus, women,s olfactory superiority has been suggested ...
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... OXFORD, England , November 4, 2014 ... expansion and vertical market growth   Fuel3D ... it has closed a funding round totaling $6.4 million (£4 ... (£1.6 million) funding secured earlier this year and paves the ... product in 2015. The funding round was led ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... the focus of the Society for Nutrition Education,s 2009 ... small step in fighting world hunger. Food security remains ... attention in order to combat the issues of poverty, ... Education (SNE) encourages its members and the public to ...
... SANTA CLARA, Calif., Oct. 9 Synaptics(R),Incorporated (Nasdaq: ... interface,solutions for mobile computing, communications, and entertainment devices,announced ... the first quarter,of fiscal 2009 on Thursday, October ... will host a corresponding conference call for analysts ...
... Researchers at the European Molecular Biology Laboratory (EMBL) have ... developmental blueprint of a vertebrate. With a newly developed ... cells for the first 24 hours in the life ... three-dimensional, digital representation of the embryo. The study, published ...
Cached Biology News:World Food Day brings attention to food security around the globe 2Synaptics to Report First Quarter Results on October 23 2Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate 2
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Yersinia pestis...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Adenylate kinase isoenzyme 6...
Biology Products: